Cannabis Cohort 2 Survey and MDH Data - Coggle Diagram
Cannabis Cohort 2 Survey and MDH Data
Pergam (2017, n=926)
- "determine the prevalence and methods of use among cancer patients, perceived benefits, sources of information in a state with legalized med/recreational program"
Anderson (2019, n=1120) - "focuses on changes in symptom severity reported by patients in first 4 months of program participation (i.e., medical cannabis use)"
Martell (2018, n=2040) - "rates of cannabis use in cancer...characterize patient perspectives about cannabis and its use"
Donovan (2019, n=816 total, 156 THC+) - "determine extent to which patients with cancer seeking specialized symptom management were using cannabis and to compare severity of cancer-related sx b/w user and non-users"
Kim (2019, n=1990) - "describe patterns of medical cannabis use by patients with cancer and how patterns differ from patients without cancer"
Saadeh (2018, n=175) - "compare incidence of cannabis use between patients with early vs advanced stage cancers)"
Key Elements of Surveys/Data
b. Cancer History (type, stage, treatments)
c. Prevalence (past and current)
e. Reasons for cannabis use
g. Patient reported benefits
h. Patient reported risks/AEs
i. Costs/financial impact
f. Cannabis use patters (types, frequency, doses)
Status of field
What is known?
a, b, and c, g
What is not well known?
What needs more clarity?
d, e, f
MDH data for validation and determining non-response bias
Detailed cannabis purchase history
Potential to explore concomitant med use/changes (do with Angela Birnbaum?)
Why do people stop using? (costs, AE, lack of effectiveness, get from outside MNCP?) --- may be hard to address with our data. only 4 patients answered no to question 9.
What type of cancer patients are using in a medical program? (update, see below methodology)
How do ongoing users differ from one time users?
How do survey responders (n=225) differ from non-responders (n= 572) in terms of demographics, co-morbidities, baseline medications (opioids/dose and other pain meds), and total number of purchases in first 3-6 months of enrollment? (update, see below methodology)
How does patient's perceived change/improvement in symptom control correlate with current cannabis product/dose?
Discuss all financial aspects of use including total costs for products purchased, household income, reported monthly cannabis spending.
consider correlation with zip codes, sociodemographic data, insurance type, occupation status
could be interesting to compare MN program/costs to other state's costs (in medical programs vs recreational program). this might lead us too far away from a cancer focus though, but could be interesting. worth seeing what MDH knows and what data they may already have.
see Jeanette's email - "Survey quality in a survey of registered medical cannabis participants with cancer: (Little?) Evidence of on-response bias and measurement error"
To what extent do responders differ from non-responders with respect to demographics, health status and cannabis use as reported in state data?
To what extent does self-report via survey align with administrative data collected by the state cannabis program?